mk-0524 and Hypertriglyceridemia

mk-0524 has been researched along with Hypertriglyceridemia* in 2 studies

Trials

1 trial(s) available for mk-0524 and Hypertriglyceridemia

Article	Year
Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome. Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:6 This study investigated the effect of long-term niacin/laropiprant therapy on CV risk and IR in obese women with PCOS.. In this double-blind randomized placebo-controlled trial, 13 and 12 PCOS women completed a 12 week course of niacin/laropiprant or placebo, respectively. Fasted subjects had an endothelial function test (EndoPat2000) and then consumed a mixed meal with blood sampled postprandially for 6 h before and after intervention.. By 12 weeks, niacin/laropiprant lowered low-density lipoprotein cholesterol (LDL-c) (13%) and increased HDL-c (17%). Despite a reduction in fasting triglycerides (21%), the drug had no effect on their postprandial rise (2.69 ± 1.44 vs. 2.49 ± 1.14 mmol/l, p = 0.72). However, following the mixed meal, plasma glucose area under the response curve increased from 13.1 ± 2.9 to 14.0 ± 2.8 mmol/l, p = 0.05, as a consequence of both increased insulin resistance [HOMA-IR: 2.2 (1.2, 4.2) vs. 3.8(1.3, 5.5), p = 0.02] and a reduced acute insulin response to glucose [424 (211, 975) vs. 257(122, 418) pmol/mmol, p = 0.04]. Niacin/laropiprant did not improve RHI (1.97 ± 0.40 vs. 2.05 ± 0.58, p = 0.33) or hsCRP.. In PCOS, niacin/laropiprant had a significant negative impact on postprandial glucose and no improvement in postprandial hypertriglyceridaemia, with at least the former mediated through increased IR and reduced β-cell function. This data may help explain why the improvement in fasting lipids has not translated into improved CV risk markers in PCOS. Topics: Adult; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Indoles; Lipid Metabolism; Niacin; Polycystic Ovary Syndrome; Postprandial Period; Risk Reduction Behavior; Treatment Outcome; Triglycerides; Young Adult	2014

Article

Year

Postprandial effects of long-term niacin/laropiprant use on glucose and lipid metabolism and on cardiovascular risk in patients with polycystic ovary syndrome.

Diabetes, obesity & metabolism, 2014, Volume: 16, Issue:6

This study investigated the effect of long-term niacin/laropiprant therapy on CV risk and IR in obese women with PCOS.. In this double-blind randomized placebo-controlled trial, 13 and 12 PCOS women completed a 12 week course of niacin/laropiprant or placebo, respectively. Fasted subjects had an endothelial function test (EndoPat2000) and then consumed a mixed meal with blood sampled postprandially for 6 h before and after intervention.. By 12 weeks, niacin/laropiprant lowered low-density lipoprotein cholesterol (LDL-c) (13%) and increased HDL-c (17%). Despite a reduction in fasting triglycerides (21%), the drug had no effect on their postprandial rise (2.69 ± 1.44 vs. 2.49 ± 1.14 mmol/l, p = 0.72). However, following the mixed meal, plasma glucose area under the response curve increased from 13.1 ± 2.9 to 14.0 ± 2.8 mmol/l, p = 0.05, as a consequence of both increased insulin resistance [HOMA-IR: 2.2 (1.2, 4.2) vs. 3.8(1.3, 5.5), p = 0.02] and a reduced acute insulin response to glucose [424 (211, 975) vs. 257(122, 418) pmol/mmol, p = 0.04]. Niacin/laropiprant did not improve RHI (1.97 ± 0.40 vs. 2.05 ± 0.58, p = 0.33) or hsCRP.. In PCOS, niacin/laropiprant had a significant negative impact on postprandial glucose and no improvement in postprandial hypertriglyceridaemia, with at least the former mediated through increased IR and reduced β-cell function. This data may help explain why the improvement in fasting lipids has not translated into improved CV risk markers in PCOS.

Topics: Adult; Blood Glucose; Cardiovascular Diseases; Cholesterol, HDL; Cholesterol, LDL; Double-Blind Method; Drug Therapy, Combination; Female; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Indoles; Lipid Metabolism; Niacin; Polycystic Ovary Syndrome; Postprandial Period; Risk Reduction Behavior; Treatment Outcome; Triglycerides; Young Adult

2014

Other Studies

1 other study(ies) available for mk-0524 and Hypertriglyceridemia

Article	Year
Paradoxical decrease in serum high-density lipoprotein cholesterol with Tredaptive® (m/r nicotinic acid 1 g and laropiprant 20 mg). Annals of clinical biochemistry, 2011, Volume: 48, Issue:Pt 6 Topics: Adult; Cholesterol, HDL; Drug Combinations; Drug Substitution; Fenofibrate; Humans; Hypertriglyceridemia; Hypolipidemic Agents; Indoles; Male; Niacin; Treatment Outcome; Triglycerides	2011